ChabioTech Strengthens R&D Capabilities by Recruiting Executives Na Hye-jeong, Kang Jae-seon, and Jang Kyung-ho

Cha Biotech has strengthened its research and development (R&D) capabilities by consecutively recruiting global experts.

ChabioTech CI
Photo by ChabioTech

On the 10th, Cha Biotech announced that it recently hired three executive directors: Na Hye-jeong, Head of Regulatory Development; Kang Jae-seon, Head of Clinical Operations; and Jang Kyung-ho, Head of Clinical Development. Following the appointment of CEO Lee Hyun-jung as co-CEO overseeing the R&D division in March, the company is continuing to enhance its capabilities by expanding its development personnel.

Head of Regulatory Development Na Hye-jeong is recognized for her extensive experience as a global regulatory lead at Samsung Biologics, Samsung Bioepis, and HanAll Biopharma, with expertise in approvals from advanced regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). She will be responsible for establishing country-specific development and regulatory strategies and managing domestic and international regulatory affairs for ongoing projects. Na stated, “I plan to elevate Cha Biotech’s regulatory capabilities to a level that meets the standards of advanced regulatory agencies like the FDA.”

Head of Clinical Operations Kang Jae-seon has experience in conducting various domestic and international clinical trials for product approvals and bringing products to market through Mokam Life Science Research Institute and GC Green Cross. Leveraging this experience, Kang will strategically plan and manage clinical trials from the early stages of development, efficiently overseeing schedules, costs, and risks throughout the development process to accelerate the commercialization of clinical projects.

Head of Clinical Development Jang Kyung-ho is a clinical pharmacology specialist who graduated from CHA University and earned a Ph.D. in medicine from Seoul National University College of Medicine. He also served as a clinical professor at Jeonbuk National University Hospital’s Biomedical Research Institute and has industry experience as a director of the clinical development team at Jin Medicine. Jang will lead the Clinical Development division, identifying foundational research suitable for commercialization and establishing clinical development strategies and protocols based on scientific evidence.

Lee Hyun-jung, CEO of the R&D division, said, “With the recruitment of these experts, we have established a global-level clinical operations system and regulatory capabilities. Based on over 20 years of accumulated experience and know-how in cell therapy research and development, Cha Biotech will accelerate the development of new cell therapy drugs.”